Patients
DEL(17)(P13), T(14;16)(Q32;Q23), MYELOMA, T(4;14)(P16;Q32)
Thirty-five consecutive patients (26 male, 9 female; mean age 59.3 years) with previously untreated MM based on the criteria established by the International Myeloma Working Group (2014) were included in this analysis (Table Patient characteristics (†High-risk cytogenetics defined as the presence of at least one of the following mutations: del(17)(p13), t(4;14)(p16;q32), or t(14;16)(q32;q23)